Halozyme Therapeutics, Inc. (HALO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $109.68 +1.14%
EPS Growth %: +30.8%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: +30.8%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q1 loss of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.5 million versus the consensus estimate of $5.19 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Halozyme prices $1.3B convertible notes offering due 2033
- IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
